Selective ALK inhibitor shows NSCLC promise
Preliminary trial results suggest that a novel, highly selective ALK inhibitor may be effective for the treatment of advanced non-small-cell lung cancer in Japanese patients with the ALK rearrangement.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine